前列腺癌患者血清EPO浓度和癌组织EPOR的表达及其临床意义  

Expression and clinical significance of erythropoietin in serum and erythropoietin receptor in cancer tissues of patients with prostate cancer

作　　者：杨祖佑[1] 黄玉华[2] 严春寅[2] 李金虎[2] 侯建全[2] 浦金贤[2] 袁和兴[2] 张光波[2] 魏雪栋[2] 

机构地区：[1]苏州市吴中人民医院泌尿外科,江苏省215128 [2]苏州大学附属第一人民医院泌尿外科

出　　处：《江苏医药》2012年第17期2055-2057,共3页Jiangsu Medical Journal

摘　　要：目的探讨前列腺癌患者血清促红细胞生成素(EPO)浓度和癌组织中促红细胞生成素受体(EPOR)的表达及临床意义。方法采用ELISA测定35例初诊前列腺癌(A组)、12例激素非依赖性前列腺癌(B组)、20例前列腺增生(C组)及15例健康人(D组)血清EPO水平;免疫组化方法检测A、C组列腺组织EPOR表达。分析A组血清EPO水平、癌组织EPOR的表达与Gleason评分、TNM分期的关系。结果 A组血清EPO水平为(32.71±26.13)mIu/ml,明显高于C组的(18.47±12.97)mIu/ml和D组的(16.41±9.37)mIu/ml(P<0.01),明显低于B组的(59.91±33.34)mIu/ml(P<0.05)。A组EPOR的表达明显高于C组(P<0.01)。A组血清EPO水平和癌组织中EPOR的表达与临床分期呈正相关(P<0.05)。结论 EPO和EPOR在前列腺癌的进展过程中可能起着重要作用。检测血清EPO水平和癌组织EPOR的表达有助于前列腺癌的诊断。Objective To investigate the expression and clinical significance of erythropoietin （EPO） in serum and erythropoietin receptor （EPOR） in cancer tissues of patients with prostate cancer. Methods Serum EPO was measured with ELISA in 35 patients with newly diagnosed prostate cancer（group A）, 12 patients with hormone-independent prostate cancer（group B）,20 patients with benign prostate hyperplasia（group C） and 15 healthy men（group D）. The expression of EPOR in the prostate was detected by immunohistochemistry in groups of A and C. The relationship of EPO and EPOR with Gleason score and TNM classification in group A was analyzed. Results Serum EPO was （32.71± 26.13 ） mIu/ml, which was significantly higher in group A than （ 32. 71 ± 26.13） mIu/ml in group C and （16.41±9. 37） mlu/ml in group D（P〈0. 01） ,but lower than （59. 91±33. 34） mIu/ml in group B（P〈0. 05）. The expression of EPOR was significantly higher in group A than that in group C （P〈0. 01）. In group A, serum EPO was positively correlated with TNM classification（P〈0. 05）. Conclusion EPO and EPOR may play an important role in the progression of prostate cancer. Detection of EPO in serum and EPOR expression in the prostate is helpful in the diagnosis of prostate

关 键 词：促红细胞生成素 促红细胞生成素受体 前列腺癌 

分 类 号：R737[医药卫生—肿瘤]